Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Chronic Venous Occlusions Treatment Market

Chronic Venous Occlusions Treatment Market Analysis

  • Report ID: GMI5398
  • Published Date: Nov 2022
  • Report Format: PDF

Chronic Venous Occlusions Treatment Market Analysis

As per product, the chronic venous occlusions treatment market is classified into devices and drugs. The drugs segment is projected to exceed USD 4.6 billion by 2030. Various drugs are utilized in the diagnosis and therapy, including analgesics, antibiotics, anticoagulants, and so on. Antibiotics are highly preferred to treat ulcers and skin infections brought on by chronic venous insufficiency. Rising demand and increased knowledge of the extensive benefits of drugs for treating chronic venous insufficiency are majorly credited for the projected segment growth.
 

The chronic venous occlusions treatment market from the edema application segment is expected to surpass a valuation of USD 2.6 billion by 2030. In 2021, a report in the PLOS Global Public Health Journal reported the prevalence of edema in around 19% of the American geriatric population. The mounting prominence of the numerous advantages offered by the available treatment options for chronic venous occlusion in the diagnosis and treatment of edema is expected to accelerate market trends.
 

Global Chronic Venous Occlusions Treatment Market By End-use

The industry is segregated in terms of end-use into hospitals, ambulatory surgical centers, and others. The ambulatory surgical centers segment accounted for 22% of the chronic venous occlusions treatment market revenue in 2021 and is expected to observe robust development over 2022-2030 due to the increasing consumer preference for ASCs for outpatient surgical procedures, quality care, cost-effectiveness, and shorter stays. The inclusion of novel treatment devices for venous ulcers, edema, DVT, and other conditions, and access to various treatments, are anticipated to foster segment value.
 

Global Chronic Venous Occlusions Treatment Market

Asia Pacific chronic venous occlusions treatment market is forecast to depict a 6.5% CAGR from 2022 to 2030. Escalating occurrences of varicose veins among adults and early diagnosis of chronic venous illnesses are enhancing product penetration, thereby supplementing APAC industry growth. In 2021, Zee News reports estimated that around 10 million Indians have varicose veins. Moreover, facilitative initiatives by government agencies and NGOs are slated to fuel the industry expansion in APAC.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for chronic venous occlusions treatment was valued at over USD 5.5 billion in 2021 and is estimated to grow significantly at a 5.5% CAGR through 2030 primarily driven by the rising awareness about available treatment options for chronic venous occlusion.

Drugs segment is projected to exceed USD 4.6 billion in revenue by 2030. The increasing awareness about the benefits of drugs for the treatment of chronic venous occlusion is anticipated to boost product demand.

Asia Pacific chronic venous occlusions treatment market is anticipated to expand at a 6.5% CAGR between 2022 and 2030 owing to the growing prevalence of varicose veins among adults and early diagnosis of chronic venous illnesses in the region.

The competitive landscape of the market includes Boston Scientific Corporation, Essity AB, Stryker Corporation, Bristol Myers Squibb, Medtronic plc, Pfizer Inc., ISOMed, Cardinal Health, SerenaGroup, Tactile Medical, Julius Zorn GmbH, Smith & Nephew PLC, Viatris Inc., Merz Pharma, Fotona, 3M Company, ConvaTec Inc., and other firms.

Chronic Venous Occlusions Treatment Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 30
  • Tables & Figures: 355
  • Countries covered: 18
  • Pages: 271
 Download Free Sample